[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 618
Citations 0
Research Letter
November 2016

The Inclusion of Nurses in Pharmaceutical Industry–Sponsored EventsGuess Who Is Also Coming to Dinner?

Author Affiliations
  • 1Faculty of Pharmacy and Charles Perkins Centre, The University of Sydney, Sydney, Australia
  • 2Centre of Research in Medical Pharmacology, University of Insubria, Varese, Italy
JAMA Intern Med. 2016;176(11):1718-1720. doi:10.1001/jamainternmed.2016.5276

The release of the Open Payments data in the United States, which detail payments from pharmaceutical and medical device companies to physicians, enables analysis of the financial relationships between physicians and industry.1 However, the Physician Payments Sunshine Act, which mandates these disclosures, omits registered nurses. A recent qualitative study suggests nurse-industry interactions in US hospitals may be common and influential.2 The limited prevalence data available, based on self-report, suggests that 51% to 96% of nurses have contact with industry representatives.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×